SCHEMBL3519735

SCHEMBL3519735

COC(=O)CCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 5/20 0.45
SLC16A7 O60669 1/20 0.41
SLC16A8 O95907 1/20 0.41
HTR5A P47898 1/20 0.41
MCL1 Q07820 1/20 0.41
ACLY P53396 1/20 0.41
SLC22A12 Q96S37 1/20 0.40
PRKD3 O94806 1/20 0.39
PRKCG P05129 1/20 0.39
PRKCB P05771 1/20 0.39
PRKCA P17252 1/20 0.39
PRKACA P17612 1/20 0.39
PRKACG P22612 1/20 0.39
PRKACB P22694 1/20 0.39
PRKCH P24723 1/20 0.39
PRKCI P41743 1/20 0.39
PRKCE Q02156 1/20 0.39
PRKCQ Q04759 1/20 0.39
PRKCZ Q05513 1/20 0.39
PRKCD Q05655 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3523363 0.94 SLC16A3 (0.43) SLC16A3SLC16A7SLC16A8HTR5AMCL1
SCHEMBL3524342 0.88 SLC16A3 (0.42) SLC16A3SLC16A7SLC16A8HTR5AACLY
SCHEMBL3522442 0.87 EDNRA (0.42) SLC16A3SLC16A7SLC16A8HTR5AACLY
SCHEMBL3526026 0.87 PTGES2 (0.50) ACLYSLC22A12CCR2
SCHEMBL3524543 0.85 KMT2A (0.58) SLC16A3SLC16A7SLC16A8HTR5AMEN1
SCHEMBL3524537 0.84 ACLY (0.47) SLC16A3SLC16A7SLC16A8HTR5AMCL1
SCHEMBL3523698 0.84 ERBB2 (0.50) ACLYKCNA5MEN1KMT2ACCR2
SCHEMBL3524790 0.84 SLC22A12 (0.61) ACLYSLC22A12MEN1KMT2ACCR2
SCHEMBL3522938 0.84 ALDH1A1 (0.53) SLC16A3MCL1MEN1KMT2ACCR2
SCHEMBL3525803 0.82 ALDH1A1 (0.48) KCNA5MEN1KMT2ACCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP SLC16A3 3744/4885SLC16A7 3821/4885SLC16A8 3938/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG SLC16A3 3322/4885SLC16A7 3308/4885SLC16A8 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.